CRNX Institutional Ownership

CRINETICS PHARMACEUTICALS IN

Latest close $84.00 as of Aug 5, 2026

Create account to watch
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.
Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing May 15, 2026
Public consensus preview Accumulation leaning 62/100 institutional research score
3 tracked institutions Latest filing May 15, 2026

1 accumulating across 1 comparable institution.

Accumulating1
Unchanged0
Reducing0
Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$24.10 52-week high$57.99
Latest close $84.00 100.0% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Mar 31, 2026
T. Rowe Price Associates May 15, 2026 filed
State Street Oct 17, 2024 filed
BlackRock Legacy Jan 25, 2024 filed
Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 4 parsed filing(s) · 1 older require more history access
Holder Observed / filed Reported change Shares Ownership Observation Filing Latest
T. Rowe Price Associates CIK0000080255 Mar 31, 2026 observed May 15, 2026 filed · 45d Schedule 13G amendment Reported accumulation 5.4M +410.3K 12.00% +5.80 pts $36.32 $36.77 $84.00
T. Rowe Price Associates CIK0000080255 Sep 30, 2024 observed Nov 14, 2024 filed · 45d Initial Schedule 13G Initial Schedule 13G 4.9M 6.20% $51.10 $59.66 $84.00
State Street CIK0000093751 Sep 30, 2024 observed Oct 17, 2024 filed · 17d Schedule 13G amendment Earliest Schedule 13G amendment found 2.8M 3.60% $51.10 $84.00
Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORP 62/100 Accumulation leaning SKT TANGER INC 62/100 Accumulation leaning SIDU SIDUS SPACE INC-CL A 62/100 Accumulation leaning LKFN LAKELAND FINANCIAL CORP 62/100 Accumulation leaning

Recent multi-institution accumulation

TVTX Travere Therapeutics, Inc. 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026